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Background
Efavirenz (EFV) treatment is associated with a range of
neuropsychiatric (NPS) adverse events (AEs), which dif-
fer in duration and severity.
Methods
In this double-blind placebo-controlled trial, 157 treat-
ment-naïve patients with HIV RNA >5000 copies/mL,
were randomised 1:1 to either etravirine (ETR) 400mg
once daily (n=79), or EFV 600mg once daily (n=78),
plus two NRTIs. After 12 weeks of randomised treat-
ment, the type and frequency of NPS AEs was compared
between treatment arms.
Results
Overall, the patients were 81% male, 85% Caucasian,
with a median age of 36 years. Median baseline CD4
Count was 302 cells/uL, median HIV RNA 4.8 log10
copies/mL. In the primary analysis, 13/79 patients
(16.5%) in the ETR arm, versus 36/78 (46.2%) in the
E F Va r m ,s h o w e da tl e a s to n eG r a d e1 - 4t r e a t m e n t -
emergent drug-related NPS AE (p<0.001). The most
common nervous system was dizziness, reported for 3
patients in the ETR arm versus 15 in the EFV arm. The
most common psychiatric adverse events were sleep dis-
orders, reported in 7 patients in the ETR arm versus 25
patients in the EFV arm. The prevalence of Grade 1-4
all cause NPS AEs showed a peak at Week 2 (21.5% in
the ETR arm and 43.6% in the EFV arm), but at the
Week 12 visit, the percentage with an ongoing Grade 1-
4 all cause NPS AE remained different between the
arms (21.7% with ETR and 35.7% with EFV). In the ETR
arm, 29 all cause NPS adverse events were reported: 20
Grade 1, 7 Grade 2 and 2 Grade 3. In the EFV arm, 93
NPS adverse events were reported: 55 Grade 1, 34
Grade 2 and four Grade 3. New medication for NPS
adverse events was started for 7.6% of patients in the
ETR arm versus 16.7% of patients in the EFV arm. One
patient in the ETR arm and five in the EFV arm discon-
tinued randomized treatment with NPS AE’s.
Conclusions
In the SENSE trial, first-line treatment with ETR 400mg
once daily +2NRTIs led to significantly fewer NPS AEs,
compared with EFV + 2NRTIs. These NPS AEs were
mainly Grade 1 or 2 in severity. The difference between
the arms emerged at Week 2, but persisted through
Week 12.
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